Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE APC and KRAS mutations and microsatellite status were determined in colorectal lesions (colorectal carcinoma (CRC), hyperplastic (HP) and adenomatous polyps (AP)). 21865138

2011

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE To compare the differences between dideoxy sequencing/KRAS StripAssay/pyrosequencing for detection of KRAS mutation in Chinese colorectal cancer (CRC) patients. 20939116

2010

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Furthermore, we examined the roles of PLCδ1 in CRC cell lines that harbor an activating KRAS mutation. 25197077

2014

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE A prospective study of 94 patients who underwent putative curative resection for colorectal carcinoma (CRC) was performed to ascertain if serum mutant KRAS2 could be used postoperatively as a disease marker. 12477769

2003

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Positive concordance of KRAS alterations between ctDNA and tissue was negatively affected by a longer time period between blood and tissue sampling and was higher in colorectal cancer than in other malignancies. 31199507

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Among protein- and gene-based chemosensitivity assays, assessment of KRAS mutation status predicts the response to epidermal growth factor receptor-targeted therapy in CRC patients. 25469008

2014

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE We investigated the efficacy of imgatuzumab in patients with EGFR-positive, KRAS-mutant advanced colorectal cancer. 24262587

2014

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE This testing also highlights the unmet need for new treatment options in KRAS mutant metastatic CRC. 20460490

2010

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE A possible importance of lacking neuroendocrine differentiation for progression of KRAS mutant CRC should be further investigated. 25337237

2014

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE The strategies to target energy metabolism for the metabolic alterations in mutated KRAS CRC are also introduced. 30341899

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Moreover, proliferation and invasion assays were conducted using cell lines. miRNA array analysis revealed that microRNA-31 (miR-31)-5p was the most up-regulated miRNA in CRCs with mutated BRAF (V600E) compared with CRCs possessing wild-type BRAF (including cases with KRAS mutation). 24242331

2014

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE TTF-1 positivity was significantly associated with distal tumour location, non-mucinous histology, intact CDX2 expression and a low frequency of KRAS mutations in CRCs. 28914964

2018

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE These results lead to new perspectives for new oral drugs in metastatic KRAS-mutated colorectal cancer resistant to standard chemotherapy. 22458846

2013

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Our results confirm an association between loss of MMR protein expression, presence of activating BRAF mutation, expanding growth, and PTL reaction as well as between tumor budding, infiltrative growth pattern, and tumor aggressiveness; however, there was no such association between the presence of an activating KRAS or BRAF mutation and a distinct invasion pattern or tumor aggressiveness in CRC. 24915895

2014

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE K-ras gene mutation status in colorectal cancer: comparative analysis of pyrosequencing and PCR-RFLP. 24068405

2013

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE The progression of colorectal cancer (CRC) involves recurrent amplifications/mutations in the epidermal growth factor receptor (EGFR) and downstream signal transducers of the Ras pathway, KRAS and BRAF. 27562229

2016

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Mucinous colorectal adenocarcinomas (MCAs) are clinically and morphologically distinct from nonmucinous colorectal cancers (CRCs), show a distinct spectrum of genetic alterations (higher KRAS mutations, lower p53, high MUC2), exhibit more aggressive behavior (more prone to peritoneal dissemination and lymph node involvement) and are associated with poorer response to chemotherapy with limited treatment options. 28640835

2017

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE KRAS and BRAF mutations are associated with inferior survival, independent of MSI status, in Japanese patients with curatively resected CRC. 25632202

2015

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Our finding that KRAS codon 13 mutations (in particular G13D) are associated with inferior survival in BRAF wild-type CRCs in Chinese patients was not reported thus far. 25367198

2014

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE KRAS mutations can be detected in approximately 30% to 40% of all patients with colorectal cancer. 19792050

2009

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE These results confirm the high prognostic value of KRAS mutations on response to cetuximab and survival in metastatic CRC patients treated with cetuximab. 18202412

2008

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE The prevalence of KRAS mutation in CRC patients with peritoneal carcinomatosis is 48% in this preliminary study and clinicopathologic factors appear to be independent of mutation status. 19952717

2010

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Thus, an unmet medical need exists to develop additional therapeutic options for patients with KRAS mutant CRC. 28353122

2017

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE APC (80-90%) and K-Ras (40-50%) mutations frequently occur in human colorectal cancer (CRC) and these mutations cooperatively accelerate tumorigenesis including metastasis. 27835580

2016

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE We investigated predictive values of BRAF, PI3K and PTEN in cetuximab responses in KRAS wild-type (+) chemotherapy refractory, metastatic colorectal cancer (CRC) patients. 23996432

2014